Jasper Therapeutics (JSPR) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company overview and strategic focus

• Clinical-stage biopharma focused on mast cell-related diseases with lead program briquilimab, a monoclonal antibody targeting c-Kit.

• Pipeline reprioritized to focus on mast cell diseases, with new trials in CSU, CIndU, and asthma.

• Significant data readouts from ongoing trials expected in Q4, with asthma trial initiation this year.

Briquilimab design and differentiation

• Humanized IgG1 antibody with a single Fc modification to minimize ADAs and avoid complement activation.

• Binds c-Kit epitope with higher affinity than natural ligand, designed for optimal mast cell targeting.

• SubQ formulation shows about 14% ADA rate, with no impact on PK/PD observed.

Clinical trial updates and design

• BEACON study (CSU) enrolls moderate to severe patients unresponsive to omalizumab, testing multiple dose levels and intervals.

• Dose selection informed by healthy volunteer study, with 80mg as threshold for significant mast cell depletion.

• Enrollment accelerated, shifting full data readout from Q3 to Q4 to provide comprehensive results.

• Data to include 12-week UAS7, UCT, tryptase, and safety for all patients; additional time points possible.